The Fox Chase Chemical Diversity Center has Completed Participation in the NIH Commercialization Accelerator Program (CAP), Based Upon NIH Grant #R44 AI125005-02 (“Development of Topical Antiviral Agents for Treating Molluscum contagiosum”)
Doylestown, PA. June 27, 2017- FCCDC has just completed participation in the NIH Commercialization Accelerator Program (CAP), based upon NIH Grant #R44 AI125005-02 (“Development of Topical Antiviral Agents for Treating Molluscum contagiosum”, R. Scott, PI), a program of study in collaboration with Prof. R. Ricciardi of the University of Pennsylvania. The CAP program was a valuable experience for us. For example, the CAP program prompted us to clarify the competitive landscape on our technology platform, making our investor pitch more compelling overall.